Synthetic Lethality Explained: Targeting Cancer’s DNA Repair Weaknesses
Can precision oncology help identify cancer’s genetic weaknesses and turn them into therapeutic opportunities? In this episode of "Rx for Biotech", host Chris Leidli speaks with Oren Gilad, CEO of Aprea Therapeutics, about the rapidly evolving field of synthetic lethality, DNA damage response, and targeted cancer therapies designed to exploit vulnerabilities in cancer cells. Oren shares how his scientific journey began at the University of Pennsylvania, where early experiments studying ATR helped shape the foundation for Aprea’s current cancer drug development strategy. That work led to a…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.